Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Well‐tolerated, ribavirin‐free, pangenotypic hepatitis C virus (HCV) treatments for transplant recipients remain a high priority. Once‐daily glecaprevir/pibrentasvir demonstrates high rates of sustained virologic response at 12 weeks posttreatment (SVR12) across all major HCV genotypes (GTs). This t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepatology
Main Authors: Reau, Nancy, Kwo, Paul Y., Rhee, Susan, Brown, Robert S., Agarwal, Kosh, Angus, Peter, Gane, Edward, Kao, Jia‐Horng, Mantry, Parvez S., Mutimer, David, Reddy, K. Rajender, Tran, Tram T., Hu, Yiran B., Gulati, Abhishek, Krishnan, Preethi, Dumas, Emily O., Porcalla, Ariel, Shulman, Nancy S., Liu, Wei, Samanta, Suvajit, Trinh, Roger, Forns, Xavier
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220874/
https://ncbi.nlm.nih.gov/pubmed/29672891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.30046
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados